475 related articles for article (PubMed ID: 27666774)
1. The frequency of late-onset Pompe disease in pediatric patients with limb-girdle muscle weakness and nonspecific hyperCKemia: A multicenter study.
Ünver O; Hacıfazlıoğlu NE; Karatoprak E; Güneş AS; Sağer G; Kutlubay B; Sözen G; Saltık S; Yılmaz K; Kara B; Türkdoğan D
Neuromuscul Disord; 2016 Nov; 26(11):796-800. PubMed ID: 27666774
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness.
Lukacs Z; Nieves Cobos P; Wenninger S; Willis TA; Guglieri M; Roberts M; Quinlivan R; Hilton-Jones D; Evangelista T; Zierz S; Schlotter-Weigel B; Walter MC; Reilich P; Klopstock T; Deschauer M; Straub V; Müller-Felber W; Schoser B
Neurology; 2016 Jul; 87(3):295-8. PubMed ID: 27170567
[TBL] [Abstract][Full Text] [Related]
3. Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: A Spanish cohort.
Gutiérrez-Rivas E; Bautista J; Vílchez JJ; Muelas N; Díaz-Manera J; Illa I; Martínez-Arroyo A; Olivé M; Sanz I; Arpa J; Fernández-Torrón R; López de Munáin A; Jiménez L; Solera J; Lukacs Z
Neuromuscul Disord; 2015 Jul; 25(7):548-53. PubMed ID: 25998610
[TBL] [Abstract][Full Text] [Related]
4. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies.
Preisler N; Lukacs Z; Vinge L; Madsen KL; Husu E; Hansen RS; Duno M; Andersen H; Laub M; Vissing J
Mol Genet Metab; 2013 Nov; 110(3):287-9. PubMed ID: 24011652
[TBL] [Abstract][Full Text] [Related]
5. Screening for late-onset Pompe disease in Poland.
Jastrzębska A; Potulska-Chromik A; Łusakowska A; Jastrzębski M; Lipowska M; Kierdaszuk B; Kamińska A; Kostera-Pruszczyk A
Acta Neurol Scand; 2019 Oct; 140(4):239-243. PubMed ID: 31125121
[TBL] [Abstract][Full Text] [Related]
6. Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness.
Johnson K; Töpf A; Bertoli M; Phillips L; Claeys KG; Stojanovic VR; Perić S; Hahn A; Maddison P; Akay E; Bastian AE; Łusakowska A; Kostera-Pruszczyk A; Lek M; Xu L; MacArthur DG; Straub V
Orphanet J Rare Dis; 2017 Nov; 12(1):173. PubMed ID: 29149851
[TBL] [Abstract][Full Text] [Related]
7. Late-onset Pompe disease: what is the prevalence of limb-girdle muscular weakness presentation?
Lorenzoni PJ; Kay CSK; Higashi NS; D'Almeida V; Werneck LC; Scola RH
Arq Neuropsiquiatr; 2018 Apr; 76(4):247-251. PubMed ID: 29742245
[TBL] [Abstract][Full Text] [Related]
8. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population.
Musumeci O; la Marca G; Spada M; Mondello S; Danesino C; Comi GP; Pegoraro E; Antonini G; Marrosu G; Liguori R; Morandi L; Moggio M; Massa R; Ravaglia S; Di Muzio A; Filosto M; Tonin P; Di Iorio G; Servidei S; Siciliano G; Angelini C; Mongini T; Toscano A;
J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):5-11. PubMed ID: 25783438
[TBL] [Abstract][Full Text] [Related]
9. Screening for Pompe disease in a Portuguese high risk population.
Almeida V; Conceição I; Fineza I; Coelho T; Silveira F; Santos M; Valverde A; Geraldo A; Maré R; Aguiar TC; Mendonça C; Martins J; Medeiros L; Barroso C; Vieira JP; Moreno T; Negrão L; Dias MS; Lacerda L; Evangelista T
Neuromuscul Disord; 2017 Aug; 27(8):777-781. PubMed ID: 28554557
[TBL] [Abstract][Full Text] [Related]
10. Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease.
Savarese M; Torella A; Musumeci O; Angelini C; Astrea G; Bello L; Bruno C; Comi GP; Di Fruscio G; Piluso G; Di Iorio G; Ergoli M; Esposito G; Fanin M; Farina O; Fiorillo C; Garofalo A; Giugliano T; Magri F; Minetti C; Moggio M; Passamano L; Pegoraro E; Picillo E; Sampaolo S; Santorelli FM; Semplicini C; Udd B; Toscano A; Politano L; Nigro V
Neuromuscul Disord; 2018 Jul; 28(7):586-591. PubMed ID: 29880332
[TBL] [Abstract][Full Text] [Related]
11. Pompe disease ascertained through The Lantern Project, 2018-2021: Next-generation sequencing and enzymatic testing to overcome obstacles to diagnosis.
Sniderman King L; Pan Y; Nallamilli BRR; Hegde M; Jagannathan L; Ramachander V; Lucas A; Markind J; Colzani R
Mol Genet Metab; 2023 May; 139(1):107565. PubMed ID: 37087815
[TBL] [Abstract][Full Text] [Related]
12. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic criteria for late-onset (childhood and adult) Pompe disease.
American Association of Neuromuscular & Electrodiagnostic Medicine
Muscle Nerve; 2009 Jul; 40(1):149-60. PubMed ID: 19533647
[TBL] [Abstract][Full Text] [Related]
14. Late Onset Pompe Disease with Novel Mutations and Atypical Phenotypes.
Chawla T; Preethish-Kumar V; Polavarapu K; Vengalil S; Bardhan M; Puri R; Verma J; Christopher R; Supriya M; Nashi S; Prasad C; Nadeesh B; Nalini A
J Neuromuscul Dis; 2022; 9(2):261-273. PubMed ID: 34864681
[TBL] [Abstract][Full Text] [Related]
15. Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study.
Confalonieri M; Vitacca M; Scala R; Polverino M; Sabato E; Crescimanno G; Ceriana P; Antonaglia C; Siciliano G; Ring N; Zacchigna S; Salton F; Vianello A;
Orphanet J Rare Dis; 2019 Mar; 14(1):62. PubMed ID: 30832705
[TBL] [Abstract][Full Text] [Related]
16. Delayed diagnosis of late-onset Pompe disease in patients with myopathies of unknown origin and/or hyperCKemia.
Pérez-López J; Selva-O'Callaghan A; Grau-Junyent JM; Gallego-Galindo L; Coll MJ; García-Morillo S; Torralba-Cabeza MA; Vilardell-Tarrés M
Mol Genet Metab; 2015 Apr; 114(4):580-3. PubMed ID: 25752415
[TBL] [Abstract][Full Text] [Related]
17. Reevaluating Muscle Biopsies in the Diagnosis of Pompe Disease: A Corroborative Report.
Genge A; Campbell N
Can J Neurol Sci; 2016 Jul; 43(4):561-6. PubMed ID: 27039993
[TBL] [Abstract][Full Text] [Related]
18. A database for screening and registering late onset Pompe disease in Turkey.
Gokyigit MC; Ekmekci H; Durmus H; Karlı N; Koseoglu E; Aysal F; Kotan D; Ali A; Koytak PK; Karasoy H; Yaman A; Sengun İS; Sayin R; Tiftikcioglu BI; Soysal A; Tutkavul K; Bayrak AO; Kısabay A; Elci MA; Yayla V; Yılmaz İA; Ozdamar SE; Erdogan C; Tasdemir N; Serdaroglu Oflazer P;
Neuromuscul Disord; 2018 Mar; 28(3):262-267. PubMed ID: 29395671
[TBL] [Abstract][Full Text] [Related]
19. Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations.
Oba-Shinjo SM; da Silva R; Andrade FG; Palmer RE; Pomponio RJ; Ciociola KM; S Carvalho M; Gutierrez PS; Porta G; Marrone CD; Munoz V; Grzesiuk AK; Llerena JC; Berditchevsky CR; Sobreira C; Horovitz D; Hatem TP; Frota ER; Pecchini R; Kouyoumdjian JA; Werneck L; Amado VM; Camelo JS; Mattaliano RJ; Marie SK
J Neurol; 2009 Nov; 256(11):1881-90. PubMed ID: 19588081
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of adult Pompe disease in patients with proximal myopathic syndrome and undiagnosed muscle biopsy.
Golsari A; Nasimzadah A; Thomalla G; Keller S; Gerloff C; Magnus T
Neuromuscul Disord; 2018 Mar; 28(3):257-261. PubMed ID: 29326002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
